首页> 外文期刊>International Journal of Molecular Sciences >Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies
【24h】

Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies

机译:基于液滴数字PCR的前列腺癌患者血液活检中的雄激素受体变异体7(AR-V7)检测

获取原文
       

摘要

Androgen receptor splice variant V7 (AR-V7) was recently identified as a valuable predictive biomarker in metastatic castrate-resistant prostate cancer. Here, we report a new, sensitive and accurate screen for AR-V7 mRNA expression directly from circulating tumor cells (CTCs): We combined EpCAM-based immunomagnetic CTC isolation using the IsoFlux microfluidic platform with droplet digital polymerase chain reaction (ddPCR) to analyze total AR and AR-V7 expression from prostate cancer patients CTCs. We demonstrate that AR-V7 is reliably detectable in enriched CTC samples with as little as five CTCs, even considering tumor heterogeneity, and confirm detection of AR-V7 in CTC samples from advanced prostate cancer (PCa) patients with AR-V7 detection limited to castrate resistant disease status in our sample set. Sensitive molecular analyses of circulating tumor cells (CTCs) or circulating tumor nucleic acids present exciting strategies to detect biomarkers, such as AR-V7 from non-invasive blood samples, so-called blood biopsies.
机译:雄激素受体剪接变体V7(AR-V7)最近被确定为转移性去势抵抗性前列腺癌的重要预测生物标志物。在这里,我们报告了一种新的,灵敏且准确的,直接从循环肿瘤细胞(CTC)中筛选AR-V7 mRNA表达的方法:我们将结合使用基于IsoFlux微流体平台的EpCAM免疫磁CTC分离与液滴数字聚合酶链反应(ddPCR)进行分析前列腺癌患者CTC中的总AR和AR-V7表达。我们证明即使在考虑到肿瘤异质性的情况下,即使仅考虑到肿瘤的异质性,AR-V7仍可在富集的CTC样品中可靠地检测到,甚至只有五个CTC,并证实AR-V7检测仅限于晚期前列腺癌(PCa)患者的CTC样品中的AR-V7检测我们的样本集中有去势抵抗疾病的状况。循环肿瘤细胞(CTC)或循环肿瘤核酸的敏感分子分析提出了令人兴奋的策略,可从非侵入性血液样本中检测生物标记物,例如AR-V7,即所谓的血液活检。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号